No pipeline data
No cash flow data
Historical delivery and spending consistency. Data is limited for recently added companies.
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
| Event | Type | Confidence | Impact | Date | Status |
|---|---|---|---|---|---|
| HEALEY ALS Trial Regimen I - Topline Resultsopen_in_new Topline results from the expanded HEALEY ALS Platform Trial Regimen I expected in early Q3 2027. [Source: HEALEY ALS Trial Regimen I Expands to 240 Participants, 2026-05-26] | data readout | Expected | arrow_upwardHigh | 30 Sept 2027 | Upcoming |
| HEALEY ALS Trial Regimen I Expands to 240 Participantsopen_in_new Neurizon expands HEALEY ALS Platform Trial Regimen I from 160 to 240 participants to strengthen statistical robustness and biomarker analysis, driven by enrolment exceeding expectations. Trial timeline accelerated with last participant dosing expected Q2 2027 and topline results early Q3 2027, with no additional cost impact through topline due to philanthropic funding contribution from Mass General Brigham. | other | Confirmed | removeMed | 26 May 2026 | Completed |
| NUZ-001 Bellberry Human Research Ethics Committee (HREC) — Ethics Approval Received for NUZ-001 Oral Liquid P1 Studyopen_in_new The Bellberry Human Research Ethics Committee (HREC) approved Neurizon's Phase 1 formulation study for NUZ-001 oral liquid formulation in Australia. The study will enrol 32 healthy volunteers to generate pharmacokinetic, safety and tolerability data supporting clinical and regulatory development of NUZ-001 for ALS. | regulatory decision | Confirmed | removeMed | 12 May 2026 | Completed |